CC-90001 is under clinical development by Bristol-Myers Squibb and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect CC-90001’s likelihood of approval (LoA) and phase transition for Idiopathic Pulmonary Fibrosis took place on 08 Dec 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their CC-90001 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

CC-90001 overview

CC-90001 is under development for the treatment of idiopathic pulmonary fibrosis (IPF), solid tumors including non-small cell lung cancer (NSCLC), metastatic triple negative breast cancer (mTNBC), squamous cell carcinoma of head and neck (SCCHN), pancreatic adenocarcinoma (PAAD), renal cell carcinoma (RCC), microsatellite-stable colorectal carcinoma (MSS CRC) and sarcoma. The drug candidate is administered orally in the form of film-coated tablet. CC-90001 is a second generation JNK1 inhibitor. It was also under development for liver fibrosis.

It was under development for the treatment of non-alcoholic steatohepatitis (NASH) with stage 3 or stage 4 liver fibrosis.

Bristol-Myers Squibb overview

Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, hospitals, medical professionals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.

Quick View CC-90001 LOA Data

Report Segments
  • Innovator
Drug Name
  • CC-90001
Administration Pathway
  • Oral
Therapeutic Areas
  • Gastrointestinal
  • Oncology
  • Respiratory
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.